[go: up one dir, main page]

WO2024243429A3 - Utilisation de constructions de fusion pour une thérapie par lymphocytes t cd4+ - Google Patents

Utilisation de constructions de fusion pour une thérapie par lymphocytes t cd4+ Download PDF

Info

Publication number
WO2024243429A3
WO2024243429A3 PCT/US2024/030819 US2024030819W WO2024243429A3 WO 2024243429 A3 WO2024243429 A3 WO 2024243429A3 US 2024030819 W US2024030819 W US 2024030819W WO 2024243429 A3 WO2024243429 A3 WO 2024243429A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell therapy
fusion constructs
costar
tcr
populations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/030819
Other languages
English (en)
Other versions
WO2024243429A2 (fr
Inventor
Robert Hawkins
John Bridgeman
Jinzhou YUAN
Leyuan BAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instil Bio Inc
Original Assignee
Instil Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Inc filed Critical Instil Bio Inc
Publication of WO2024243429A2 publication Critical patent/WO2024243429A2/fr
Publication of WO2024243429A3 publication Critical patent/WO2024243429A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention propose des populations et des procédés d'utilisation de lymphocytes T CD4+ exprimant diverses constructions de fusion dans une thérapie par lymphocytes T. Les constructions de fusion permettent une cytotoxicité ciblée supérieure sur des lymphocytes T CD4+ modifiés pour exprimer un CAR ou un TCR sans une thérapie par lymphocytes T in vivo CoStAR.
PCT/US2024/030819 2023-05-24 2024-05-23 Utilisation de constructions de fusion pour une thérapie par lymphocytes t cd4+ Pending WO2024243429A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504152P 2023-05-24 2023-05-24
US63/504,152 2023-05-24

Publications (2)

Publication Number Publication Date
WO2024243429A2 WO2024243429A2 (fr) 2024-11-28
WO2024243429A3 true WO2024243429A3 (fr) 2024-12-26

Family

ID=93590464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030819 Pending WO2024243429A2 (fr) 2023-05-24 2024-05-23 Utilisation de constructions de fusion pour une thérapie par lymphocytes t cd4+

Country Status (1)

Country Link
WO (1) WO2024243429A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152451A1 (fr) * 2019-01-22 2020-07-30 Immetacyte Limited Récepteurs fournissant une costimulation ciblée pour une thérapie cellulaire adoptive
WO2022016112A1 (fr) * 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Récepteurs fournissant une costimulation ciblée destinée à une thérapie cellulaire adoptive

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152451A1 (fr) * 2019-01-22 2020-07-30 Immetacyte Limited Récepteurs fournissant une costimulation ciblée pour une thérapie cellulaire adoptive
WO2022016112A1 (fr) * 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Récepteurs fournissant une costimulation ciblée destinée à une thérapie cellulaire adoptive

Also Published As

Publication number Publication date
WO2024243429A2 (fr) 2024-11-28

Similar Documents

Publication Publication Date Title
WO2020168317A8 (fr) Cellules souches donnatrices universelles et méthodes associées
WO2022040586A3 (fr) Compositions et méthodes pour la génération in vivo de cellules exprimant car
WO2020096986A3 (fr) Sélection de lymphocytes t réactifs à une tumeur améliorés
WO2012156958A8 (fr) Lignée cellulaire de lymphocytes comprenant des lymphocytes t gamma-delta, composition et procédé de préparation de celle-ci
MX390753B (es) Metodos para reprogramar celulas y usos de los mismos.
WO2018005521A3 (fr) Chambres de culture cellulaire et leurs procédés d'utilisation
WO1997015655A3 (fr) Nouveaux tissus artificiels, procede de fabrication correspondant et utilisation
EP3018217A3 (fr) Gène restaurateur rf4 de type c de stérilité masculine cytoplasmique de maïs, marqueurs moléculaires et leur utilisation
CA3177413A1 (fr) Selection de lymphocytes t reactifs a une tumeur ameliores
WO2023004367A3 (fr) Compositions de ciblage modifiées pour cellules endothéliales du système vasculaire du système nerveux central et leurs procédés d'utilisation
WO2001007568A3 (fr) Cellules musculaires et leur utilisation dans la reparation cardiaque
SI1948789T1 (sl) Postopek za pridobivanje permanentnih humanih celičnih linij
WO2008036421A3 (fr) Amélioration apportée par le reishi de l'adhesion et de la differentiation cellulaires progénitrices de tissu humain
WO2011017151A3 (fr) Méthodes d'appariement pour la préparation de lymphocytes t cytotoxiques alloréactifs
WO2024073723A3 (fr) Anticorps anti-cd122 et leurs utilisations
WO2023018990A3 (fr) Lipides pour l'administration d'acides nucléiques
EP1942925A4 (fr) Procedes d'administration de polypeptides de fusion dans une cellule
WO2021226543A3 (fr) Récepteurs d'antigènes chimériques (car) ciblant des cellules tueuses naturelles
WO2023007443A3 (fr) Matrice de fibres à échelle hybride à forme de particules
EP4253422A3 (fr) Anticorps liant un tissu tumoral et leurs utilisations diagnostiques et thérapeutiques
WO2024243429A3 (fr) Utilisation de constructions de fusion pour une thérapie par lymphocytes t cd4+
CA3256099A1 (fr) Hydrogels à solution unique avec liaison covalente formée in situ, conception de composition et procédures médicales utilisant les hydrogels
MX2023002741A (es) Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas.
CA3198027A1 (fr) Cellules, tissus, organes et animaux ayant un ou plusieurs genes modifies pour une survie et une tolerance de xenogreffe ameliorees
BR0314402A (pt) Expansão ex-vivo de populações de células raìzes em culturas celulares mononucleares